American Cancer Society updates prostate cancer screening guidelines

· News-Medical

The American Cancer Society has updated its prostate cancer screening guidelines to recommend prostate-specific antigen (PSA) screening every two years for average-risk men ages 50-69 and annual screening starting at age 45 for Black men and men with significant family history of the disease.

"For the first time, we are making a proactive recommendation for men to screen for prostate cancer with the prostate-specific antigen blood test," said Wolf, professor emeritus of medicine at the University of Virginia School of Medicine and chair of the American Cancer Society's Guideline Development Group. "It's now clear that the benefits of screening in terms of reducing the risk of dying from prostate cancer or being diagnosed with late-stage disease outweigh the potential downsides of the screening."

Prostate cancer is the most commonly diagnosed cancer and second-leading cause of cancer deaths among men in the United States, killing more than 36,000 each year. Death rates are roughly twice as high in Black men as in white men.

"PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits," said the new guidelines' senior author, Robert Smith, PhD, senior vice president of early cancer detection science and director of the Center for Early Cancer Detection at the ACS. "We also have better approaches to catching lethal tumors while avoiding unnecessary tests for slow-growing cancers that may never need aggressive care. The PSA test is just the first step in a screening process. Secondary testing for men with elevated PSA levels determines who needs a biopsy … and, if so, who needs immediate treatment and who can be safely monitored via active surveillance."

Other screening recommendations include:

  • Doctors should take an individualized approach to helping men ages 70 to 74 determine if they should continue screening, basing the decision on potential risks and rewards. (Because prostate cancer tends to grow very slowly, patients at this age may want to discontinue screening to avoid the chances of a false positive, the need for a biopsy, etc.)
  • Screening is not recommended for men ages 75 or older. Some healthy men who are 75 to 79 may want to continue screening, especially if their PSA has been rising. But they should discuss this with their doctor.
  • Screening is not recommended for men 80 or older, or for men not expected to live another 10 years.
  • Men with elevated PSA between ages 45 and 74 should undergo repeat PSA testing between two weeks and three months after their initial test.
  • Elevated PSA should be confirmed by magnetic resonance imaging (MRI) and/or testing with a urine or blood biomarker (biological indicator) to determine if a biopsy is needed.
  • Men diagnosed with prostate cancer that has a low risk of growing or spreading should be offered "active surveillance" – close monitoring – as the first treatment option, rather than a more aggressive tactic.

Wolf and colleagues at UVA Comprehensive Cancer Center work diligently to improve cancer detection, develop better cancer treatments and, ultimately, save lives. UVA's cancer center is one of only 58 in the country to earn the elite "comprehensive" designation from the National Cancer Institute in recognition of their exceptional patient care and cutting-edge cancer research.

Guidelines published

Source:

University of Virginia Health System

Journal reference: